Home・Akciju saraksts・MediciNova Inc

MediciNova Inc

Slēgts

SektorsVeselības aprūpe

1.31 1.55

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

1.28

Max

1.31

Galvenie mērījumi
By Trading Economics
Ienākumi	216K -2.6M
Pārdošana	35K 187K
EPS	-0.05
Peļņas marža	-1,383.144
Darbinieki	6
EBITDA	312K -2.5M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+501.5% upside

Dividendes
By Acuity
Nākamie ieņēmumi	2026. g. 12. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-4.4M 65M
Iepriekšējā atvēršanas cena	-0.24
Iepriekšējā slēgšanas cena	1.31

Ziņu noskaņojums

By Acuity

43%

57%

135 / 340 Rangs Healthcare

MediciNova Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 3. aug. 20:06 UTC

MediciNova Inc. shares are lower, continuing a decline since Friday's close, despite positive movements in major indices like the S&P 500 and Nasdaq 100.

2026. g. 31. jūl. 19:56 UTC

Shares of MediciNova Inc. are lower during Friday's session, following a routine decline after an early high. The stock is below its 20-day moving average.

2026. g. 30. jūl. 20:51 UTC

MediciNova Inc's shares are lower in after-market hours, reflecting a broader decline in the Biotechnology sub-sector. The asset is near its one-month trading range low.

2026. g. 29. jūl. 20:09 UTC

MediciNova Inc shares are lower today, continuing a decline since Tuesday's close, and remain near their opening low amid broader market trends.

2026. g. 28. jūl. 18:46 UTC

MediciNova Inc. shares are trading higher today, remaining above Monday's close despite settling back from earlier gains during the session.

2026. g. 27. jūl. 19:06 UTC

MediciNova Inc. shares are lower today, reflecting broader market trends amid a significant decline in crude oil prices following eased geopolitical tensions.

2026. g. 24. jūl. 23:02 UTC

MediciNova Inc shares increased in after-hours trading, reflecting strong performance since Friday's close, despite mixed market sentiment and no specific company news.

2026. g. 23. jūl. 20:06 UTC

MediciNova Inc. shares are lower today, continuing a six-session decline amid routine volatility and remaining significantly below the 20-day moving average.

2026. g. 21. jūl. 19:21 UTC

MediciNova Inc. shares are lower amid no specific news, continuing a trend below the 20-day moving average over the past three sessions.

Salīdzinājums

Cenas izmaiņa

MediciNova Inc Prognoze

Cenas mērķis

By TipRanks

501.5% augšup

Prognoze 12 mēnešiem

Vidējais 8 USD 501.5%

Augstākais 10 USD

Zemākais 6 USD

Pamatojoties uz 2 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi MediciNova Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

2 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 2 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam MediciNova Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

135 / 340 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par MediciNova Inc

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.